Altimmune (MEX:ALT1) Short-Term Debt: MXN0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ALT1 Altimmune Inc MEX:ALT1
28 GF Score
Price MXN48.50
! 2 Warning Signs
View Full Analysis

What is Altimmune Short-Term Debt?

Altimmune MEX:ALT1 28 Short-Term Debt is MXN0.00 Mil as of Mar. 2026. GuruFocus rates MEX:ALT1 with a GF Score™ of 28/100. The stock has 2 warning signs investors should review.

Altimmune's Short-Term Debt for the quarter that ended in Mar. 2026 was MXN0.00 Mil.

Altimmune Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Altimmune Short-Term Debt Related Terms

Altimmune Short-Term Debt Historical Data

* Premium members only.

The historical data trend for Altimmune's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Altimmune Short-Term Debt Chart

Altimmune Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Altimmune Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:ALT1
28GF Score
Altimmune Inc MEX:ALT1
Short-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Short-Term Debt →
What does a Short-Term Debt of MXN0.00 Mil mean?
Altimmune (MEX:ALT1) has a Short-Term Debt of MXN0.00 Mil as of Mar. 2026.
Is Altimmune's Short-Term Debt too high?
Altimmune's current Short-Term Debt is MXN0.00 Mil. Overall, Altimmune has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Altimmune's Short-Term Debt compare to VSTM and PRME?
Altimmune's Short-Term Debt of MXN0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Short-Term Debt for a Biotechnology company?
A good Short-Term Debt depends on the Biotechnology industry context. However, Short-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Short-Term Debt mean?
A high Short-Term Debt can signal that a stock is expensive relative to its fundamentals. Altimmune's current Short-Term Debt is MXN0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Altimmune stock overvalued right now?
Altimmune (MEX:ALT1) has a current Short-Term Debt of MXN0.00 Mil. The current Short-Term Debt is MXN0.00 Mil. Altimmune's overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Short-Term Debt calculated?
Short-Term Debt is calculated from a company's financial statements. For Altimmune (MEX:ALT1), the current Short-Term Debt is MXN0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Altimmune Business Description

Other Exchanges ALT:USA0A4C:UK3G0:Germany
Address 910 Clopper Road, Suite 201S, Gaithersburg, MD, USA, 20878
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
28GF Score

Get the complete analysis for MEX:ALT1

Short-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.50
Price